Icon (NASDAQ:ICLR) Shares Unloaded Rep. Kevin Hern

Key Points

• Representative Kevin Hern disclosed selling $100,001–$250,000 of Icon Plc (ICLR) stock on March 5 from the HERN FAMILY REVOCABLE TRUST.
• Icon shares were reported down about 4%, opening at $109.62 and trading in a 12‑month range of $66.57–$211.00, with a market cap around $8.85 billion and a P/E of roughly 14.8.
• Analysts are mixed—seven Buy, seven Hold and three Sell—yielding a consensus rating of "Hold" with a $148.80 consensus price target, while institutional investors own about 95.61% of the stock.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Icon Plc NASDAQ: ICLR. In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $100,001 and $250,000 in Icon stock on March 5th. The trade occurred in the Representative's "HERN FAMILY REVOCABLE TRUST" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Exact Sciences NASDAQ: EXAS on 3/24/2026.
• Sold $50,001 - $100,000 in shares of Prologis NYSE: PLD on 3/20/2026.
• Sold $15,001 - $50,000 in shares of T. Rowe Price Group NASDAQ: TROW on 3/20/2026.
• Sold $15,001 - $50,000 in shares of Medtronic NYSE: MDT on 3/20/2026.
• Sold $500,001 - $1,000,000 in shares of Texas Instruments NASDAQ: TXN on 3/18/2026.
• Sold $500,001 - $1,000,000 in shares of Smartstop Self Storage REIT NYSE: SMA on 3/18/2026.
• Sold $50,001 - $100,000 in shares of BlackRock MuniAssets Fund NYSE: MUA on 3/17/2026.
• Sold $15,001 - $50,000 in shares of Cognizant Technology Solutions NASDAQ: CTSH on 3/17/2026.
• Sold $15,001 - $50,000 in shares of Invesco NYSE: IVZ on 3/17/2026.
• Sold $15,001 - $50,000 in shares of Becton, Dickinson and Company NYSE: BDX on 3/17/2026.

Icon Trading Down 4.0%

NASDAQ ICLR opened at $109.62 on Tuesday. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00. The company has a 50-day moving average of $117.59 and a 200-day moving average of $157.40. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The company has a market cap of $8.85 billion, a P/E ratio of 14.83, a P/E/G ratio of 2.89 and a beta of 1.28.

Analyst Ratings Changes

A number of research firms have recently commented on ICLR. BMO Capital Markets raised shares of Icon from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $100.00 to $130.00 in a research note on Thursday, March 26th. Citigroup dropped their price objective on shares of Icon from $200.00 to $120.00 and set a "neutral" rating for the company in a research note on Wednesday, March 11th. Leerink Partners reaffirmed a "market perform" rating and set a $105.00 price objective on shares of Icon in a research note on Thursday, February 12th. Barclays decreased their target price on Icon from $200.00 to $120.00 and set an "equal weight" rating for the company in a report on Monday, March 9th. Finally, TD Cowen upgraded Icon from a "hold" rating to a "buy" rating and decreased their target price for the stock from $183.00 to $120.00 in a report on Wednesday, February 18th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Icon currently has an average rating of "Hold" and a consensus price target of $148.80.

Institutional Trading of Icon

A number of institutional investors have recently modified their holdings of ICLR. Muhlenkamp & Co. Inc. purchased a new position in Icon in the 3rd quarter worth approximately $12,857,000. Mitchell Capital Management Co. purchased a new position in Icon in the 3rd quarter worth approximately $1,627,000. First National Bank of Omaha purchased a new position in Icon in the 3rd quarter worth approximately $6,267,000. Tributary Capital Management LLC boosted its holdings in Icon by 84.5% in the 3rd quarter. Tributary Capital Management LLC now owns 11,752 shares of the medical research company's stock worth $2,057,000 after acquiring an additional 5,381 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Icon by 1.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,080,192 shares of the medical research company's stock worth $203,800,000 after acquiring an additional 11,335 shares during the period. Hedge funds and other institutional investors own 95.61% of the company's stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Icon

Icon plc NASDAQ: ICLR is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon's service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.